BioSpace News Archive

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival Opdivo is the first and only treatment to demonstrate superior efficacy in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and resection Second tumor, in addition to melanoma, where Opdivo ha

bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed Denice Torres to its Board of Directors. “We’re excited to welcome Denice to the Board to help guide bluebird as we reach the next stage in our evolution,” said Nick Leschly, chief bluebird. “Denice brings valuable perspective and exceptional industry insights based on over 25 years of executive management experience in pharmaceuticals, medic

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today reported financial results for the second quarter ended June 30, 2020 .

Tony Hale opens up about his personal experiences to help educate other asthma sufferers on the importance of personalized care

• Obtained U.S. FDA Fast Track designation for BDTX-189 for the treatment of adult patients with a solid tumor harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20 insertion mutation • Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021 • Strengthened executive team with the appointment of Fang Ni, Pharm.D., as Chief Business Officer • Cash, cash equivalents, and in

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has commenced its previously disclosed rights offering.

The NIAID funded grant will help advance AUM LifeTech’s preclinical program on HIV therapy using self-delivering RNA silencing technology

Immuneering Corporation announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020.

American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program . AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area, and has named Washington Health Institute, University of Maryland, Institute of Human Virology and Georgetown University as its initial trial sites. These sites are expected to

Queset Medical, Inc.,(https://quesetmedical.com/) a leading distributor of supplies for pulmonary function testing, has a complete line of PFT Anti-Viral filters that comply with recent guidance for spirometry testing during the Corona Virus pandemic.